# Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

> **NCT00006267** · PHASE2 · WITHDRAWN · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** rubitecan

## Key facts

- **NCT ID:** NCT00006267
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Never activated.
- **Last updated:** 2013-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006267, "Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*